Read Time:59 Second
Researchers at NYU Langone Health in New York are investigating CAR-T therapy as a novel treatment for systemic lupus erythematosus (SLE), a complicated autoimmune disorder. SLE causes the immune system to mistakenly attack the body’s own tissues, resulting in inflammation and damage across various organs. This disease is often challenging to diagnose and manage.
Dr. Amit Saxena, Director of the Lupus Clinical Research Program at NYU Langone Health, has reported encouraging early findings from clinical trials using CAR-T therapy. This innovative treatment employs specially engineered immune cells that target and eliminate the harmful cells responsible for lupus. Unlike existing therapies which mainly control symptoms and aim for remission, CAR-T therapy holds the potential to offer a long-term cure.
Although still in the initial stages, these trials indicate that CAR-T therapy may safely reduce lupus activity in patients who have not responded well to traditional treatments. If proven effective, this approach could transform lupus treatment in the future.
Both researchers and patients are optimistic about these advancements. Further studies will determine whether CAR-T therapy can become a standard care option for lupus sufferers.
Stay tuned for more updates from Questiqa USA.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
Average Rating